- Home
- WENC vs ACOG Comparison
WENC vs ACOG Comparison
Compare WENC & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | WENC | ACOG |
|---|---|---|
| Founded | 2025 | 2000 |
| Country | Mexico | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.2M | 180.5M |
| IPO Year | 2026 | 2024 |
Fundamental Metrics
Financial Performance| Metric | WENC | ACOG |
|---|---|---|
| Price | $10.04 | $8.81 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | 66.4K | ★ 102.8K |
| Earning Date | N/A | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 41.58 |
| EPS | ★ 0.06 | N/A |
| Revenue | N/A | ★ $10,220,275.00 |
| Revenue This Year | N/A | $153.46 |
| Revenue Next Year | N/A | $85.72 |
| P/E Ratio | $167.65 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.89 | $4.50 |
| 52 Week High | $10.06 | $10.14 |
Technical Indicators
Market Signals| Indicator | WENC | ACOG |
|---|---|---|
| Relative Strength Index (RSI) | 58.11 | 52.93 |
| Support Level | $9.92 | $7.62 |
| Resistance Level | N/A | $9.21 |
| Average True Range (ATR) | 0.02 | 0.50 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 72.46 | 62.13 |
Price Performance
Historical ComparisonAbout WENC West Enclave Merger Corp. Ordinary Shares
West Enclave Merger Corp is a blank check company.
About ACOG Alpha Cognition Inc.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimers disease, for which there are limited or no treatment options. The Companies current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Companies commercial development program for ZUNVEYL is focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.